FDA.reportPublic FDA data

CABOTEGRAVIR Pharmacologic Class Indexing

Class set ID
206cbf39-b2a4-42a2-abf4-8013d81fdbb0
Version
2
Effective date
20210805
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use Initial U.S. Approval: 2021ViiV Healthcare Company | Glaxo Wellcome Manufacturing Pte. Ltd | Janssen Pharmaceutica NV2025112616
These highlights do not include all the information needed to use APRETUDE safely and effectively. See full prescribing information for APRETUDE. APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use Initial U.S. Approval: 2021ViiV Healthcare Company202504118
These highlights do not include all the information needed to use VOCABRIA safely and effectively. See full prescribing information for VOCABRIA. VOCABRIA (cabotegravir) tablets, for oral use Initial U.S. Approval: 2021ViiV Healthcare Company202504118